GeneVentiv to Attend Biotech Showcase

November 30, 2023

Damon R. Race, President & CEO

RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the Biotech Showcase and BIO Partnering meetings during the J.P. Morgan Healthcare Conference, which will be held in San Francisco, CA from January 8-10, 2024.  GeneVentiv will meet with prospective investors and present GENV-HEM, GeneVentiv’s lead AAV-based gene therapy which has an FDA Orphan Drug Designation for hemophilia A or B with or without inhibitors.

About GeneVentiv:

GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood disorders.  Our lead program, GENV-HEM (AAV8.FVa), is the only single infusion, universal, AAV-based gene therapy able to treat all types of hemophilia.  Unlike other AAV-based hemophilia gene therapies, GENV-HEM is the only gene therapy able to treat the 33% of hemophilia patients with neutralizing antibodies (inhibitors) to their missing clotting factor.  There are 50,000 inhibitor patients in the developed world.  Approved, single infusion, gene therapies for non-inhibitor patients are priced between $2.9M and $3.5M.  GENV-HEM has received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors and a Letter of Support from the National Bleeding Disorders Foundation.